Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones
Portfolio Pulse from
Ultragenyx has reported preliminary 2024 revenue figures, exceeding the top end of their guidance with total revenue expected between $555 million and $560 million. This includes Crysvita® revenue of $405 million to $410 million and Dojolvi® revenue of $87 million to $89 million.
January 12, 2025 | 4:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ultragenyx's preliminary 2024 revenue exceeds expectations, with significant contributions from Crysvita® and Dojolvi®. This positive revenue outlook may boost investor confidence.
Ultragenyx's preliminary revenue figures for 2024 exceed the top end of their guidance, indicating strong performance. The significant revenue from Crysvita® and Dojolvi® suggests robust product demand, likely to positively impact investor sentiment and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100